Since CD36 is also expressed in a subset of GBM cells, engineered mesenchymal stem cells expressing TSR3 have been employed to sensitize GBM cells to TRAIL-mediated apoptosis through activation of CD36 signaling and upregulation of DR4/DR5 TRAIL receptors (Choi et al., 2015). This evidence concerns the gene TSR3 and glioblastoma.